SWOG clinical trial number
CTSU/EAY131

Molecular Analysis for Therapy Choice (MATCH)

Closed
Phase
Abbreviated Title
MATCH
Status Notes
Activated: 8/12/2015, with Addendum 1.
(Pre-Activated by CTSU 5/29/2015 and SWOG on 7/15/2015). Sites must utilize CIRB as IRB of record to participate in the protocol.

***See CTSU for subprotocol status notes***
Activated
05/29/2015
Closed
09/27/2022
Participants
CTSU

Research committees

Early Therapeutics & Rare Cancers
Breast Cancer
Genitourinary Cancer
Lung Cancer
Lymphoma
Melanoma
Myeloma

Eligibility Criteria Expand/Collapse

***See protocol abstract page on the CTSU website (www.ctsu.org) for each subprotocol for protocol-specific eligibility criteria.

Publication Information Expand/Collapse

2025

Phase II Study of Copanlisib in Patients With PTEN Loss: Results From NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols Z1G and Z1H

Gouda MA JCO Precis Oncol. 2025 Feb;9:e2400451. doi: 10.1200/PO-24-00451. Epub 2025 Feb 6.NIHMS2058197

PMid: PMID39913886 | PMC number: PMC12002398

Concordance between Tumor Tissue and Plasma DNA Genotyping in the NCI-MATCH Trial (EAY131)

Gouda MA Clin Cancer Res. 2025 Oct 15;31(20):4299-4310. doi: 10.1158/1078-0432.CCR-24-3531.NIHMS2084882

PMid: PMID40388547 | PMC number: PMC12383705

2024

Phase II Trial of Afatinib in Patients With EGFR-Mutated Solid Tumors Excluding Lung Cancer: Results From NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol A

S Gettinger;Z Song;K Reckamp;J Moscow;R Gray;V Wang;L McShane;L Rubinstein;D Patton;P Willams;S Hamilton;X Kong;J Tricoli;B Conley;C Arteaga;L Harris;P O'Dwyer;A Chen;K Flaherty JCO Precision Oncology Jul:8:e2300725

PMid: PMID38986051

2023

Phase II Study of Palbociclib (PD-0332991) in CCND1, 2, or 3 Amplification: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1B

A Clark;F Hong;R Finn;A DeMichelle;E Mitchell;J Ziebel;F Arnaldez;F Arnaldez;R Gray;V Wang;L McShane;L Rubinstein;D Patton;P Willams;S Hamilton;M Copur;S Kasbari;R Thind;B Conley;C Arteaga;P O'Dwyer;L Harris;A Chen;K Flaherty Clinical Cancer Research

PMid: PMID36853016 | PMC number: PMC10102836

Other Clinical Trials

SWOG Clinical Trial Number
CTSU-A012303

Shortstop-HER2: Shortened Duration of Adjuvant Therapy in Patients with Early-Stage HER2+ Breast Cancer who Achieve PCR After Neoadjuvant Chemotherapy with HER2 Blockade
Research Committee(s)
Breast Cancer
Activated
07/25/2025
Open
Phase
SWOG Clinical Trial Number
CTSU-A012301

LoTam: A Randomized, Phase III Clinical Trial of Low-Dose Tamoxifen for Selected Patients with Molecular Low-Risk Early-Stage Breast Cancer
Research Committee(s)
Breast Cancer
Activated
02/05/2025
Open
Phase
SWOG Clinical Trial Number
S2206

A Randomized trial of neoadjuvant durvalumab plus chemotherapy versus chemotherapy alone for Adults with MammaPrint Ultrahigh (MP2) hormone receptor (HR) positive /Human Epidermal Growth Factor receptor (HER2) negative stage II-III breast cancer
Research Committee(s)
Breast Cancer
Symptom Management and Survivorship
Activated
10/30/2023
Accrual
38%
Open
Phase